Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

A Resized Recall Image cb1February 22 2018

Two Class 2 Drug alerts have been issued recalling two batches of Ventolin and one batch of Seretide which incorporate the Accuhaler.

The first recall is for the following batches of Ventolin Accuhaler 200mcg (salbutamol sulfate) 60 doses:

Lot Number Expiry Date First Distributed
786G 05-2019 October 2 2017
754P 05-2019 August 31 2017

The other recall is for Seretide Accuhaler 50 microgram/250 microgram/dose inhalation powder, pre-dispensed 60 dose inhaler, with lot number 5K8W, and expiry 04-2019, first distributed on August 29 2017.

The MHRA says the recalls for the Glaxo Wellcome Ltd products are due to a manufacturing issue which has resulted in a small number of units not delivering the full number of doses.

Affected inhalers should be quarantined. Pharmacists are being asked to contact patients who may have been supplied a product from the affected batches to advise them about returning the inhaler for a replacement.

Further information is available from GlaxoSmithKline on 0800 221 441 (option 4) for medical enquiries and 0800 221 441 (option 1) for stock enquiries.

Links:
MHRA recall for Ventolin         
MHRA recall for Seretide         

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...